News Releases

Date Title and Summary Additional Formats
Toggle Summary Avid Bioservices to Present at the 30th Annual ROTH Conference
TUSTIN, Calif. , March 06, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices to Report Financial Results for Third Quarter of Fiscal Year 2018 After Market Close on March 12, 2018
TUSTIN, Calif. , March 05, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Selected by Acumen Pharmaceuticals to Lead Process Development and Clinical Manufacture of Novel Alzheimer's Disease Candidate
TUSTIN, Calif. , March 01, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a dedicated contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and
View HTML
Toggle Summary Avid Bioservices Announces Resignation of Chief Financial Officer
Search for Replacement has Commenced
View HTML
Toggle Summary Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
TUSTIN, Calif. , Feb. 21, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that Enzyvant, a subsidiary of
View HTML
Toggle Summary Avid Bioservices Announces Closing of Public Offering of Common Stock
TUSTIN, Calif. , Feb. 20, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) today announced the closing of its previously announced underwritten public offering of 10,294,445 shares of its common stock, including 1,294,445 shares sold pursuant to the underwriters'
View HTML
Toggle Summary Avid Bioservices Announces Pricing of Public Offering of Common Stock
TUSTIN, Calif. , Feb. 15, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) today announced the pricing of an underwritten public offering of 9,000,000 shares of its common stock at a price to the public of $2.25 per share. The gross proceeds from this offering are
View HTML
Toggle Summary Avid Bioservices Announces Proposed Offering of Common Stock
TUSTIN, Calif. , Feb. 14, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) today announced that it has commenced an underwritten public offering of its common stock.  Avid Bioservices also intends to grant the underwriter a 30-day option to purchase from it up to an
View HTML
Toggle Summary Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid's PS-Targeting Program Including Bavituximab
TUSTIN, Calif. and BOSTON , Feb. 12, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP) ("Avid") and Oncologie, Inc. today announced that the companies have entered into an Asset Assignment and Purchase Agreement for Avid's phosphatidylserine (PS)-targeting program
View HTML
Toggle Summary Avid Bioservices to Present at NobleCon14
TUSTIN, Calif. , Jan. 23, 2018 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO) (NASDAQ:CDMOP), a company working to improve patient lives by providing high quality biologics manufacturing services to biotechnology and pharmaceutical companies, today announced that its president and chief
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO)
Company Adopts "CDMO" as New Nasdaq Ticker Symbol; Will Initiate Trading Under New Ticker on January 8, 2018
View HTML
Toggle Summary Peregrine Pharmaceuticals to Present at Biotech Showcase 2018
TUSTIN, Calif. , Jan. 02, 2018 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced that its president and chief executive officer, Roger J.
View HTML
Toggle Summary Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer
TUSTIN, Calif. , Dec. 26, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a company committed to improving patient lives by manufacturing and delivering high quality biologics, today announced the appointment of Roger J.
View HTML
Toggle Summary Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments
-- Avid Bioservices Records Revenues of $12.8 Million in the Second Quarter of FY2018 --                -- Transition to a Dedicated CDMO Business Nearing Completion -- TUSTIN, Calif. , Dec. 11, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc.
View HTML
Toggle Summary Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock
TUSTIN, Calif. , Dec. 07, 2017 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (Nasdaq:PPHM) (Nasdaq:PPHMP) today announced that its Board of Directors has declared a quarterly cash dividend payment on the Company's 10.50% Series E Convertible Preferred Stock (the "Series E Preferred Stock").
View HTML